Browsing Tag
Eli Lilly and Company
140 posts
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
MeiraGTx signs $475m ophthalmology gene therapy collaboration with Eli Lilly
MeiraGTx Holdings plc signed a USD 475 million gene therapy deal with Eli Lilly and Company to develop AAV-AIPL1 and apply riboswitch tech in ophthalmology.
Eli Lilly (NYSE: LLY) to build $3bn Netherlands plant to power global obesity drug supply
Find out how Eli Lilly’s $3 billion Netherlands plant will reshape obesity drug manufacturing and strengthen Europe’s pharma supply chain resilience.
Will orforglipron turn Eli Lilly into the king of GLP-1s? The FDA decision that could change obesity care
Eli Lilly is stockpiling orforglipron pills ahead of FDA approval. Explore the risks, rewards, and why investors are paying close attention to this launch.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Could Eli Lilly and Incyte’s Olumiant redefine how adolescent alopecia areata is treated in 2025?
Find out how Eli Lilly and Incyte's Olumiant helped teens regrow hair in a new trial—could this redefine alopecia areata treatment for adolescents?
Lilly’s $262m Adverum Biotechnologies buyout marks a major push into ocular gene therapy
Find out how Eli Lilly’s $262 million Adverum Biotechnologies buyout is advancing gene-therapy innovation in vision care!
Inside Shuttle Pharmaceuticals’ $10m AI gamble: How Molecule.ai could rewrite drug discovery timelines
Shuttle Pharmaceuticals to acquire Molecule.ai for $10M, entering AI-driven drug discovery. See how this bold move could reshape SHPH’s biotech future.
Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data
Eli Lilly’s Omvoh (mirikizumab-mrkz) delivers four years of steroid-free remission in ulcerative colitis patients according to LUCENT-3 data. Discover how this sets a new benchmark for IBD therapy.
Factory shock at Clayton: Why Novo Nordisk is cutting jobs even as it expands in America’s GLP-1 boom
Find out how Novo Nordisk’s U.S. factory job cuts fit into its $4.1 billion expansion—and what it means for Wegovy, Ozempic, and GLP-1 growth in 2025.